NCT07198685View on ClinicalTrials.gov

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

NANot yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Treat to TargetTreatment Duration
Interventions
DRUG

bedaquiline

Administer 400 mg orally once daily for 2 weeks, followed by 200 mg orally three times a week for 22 weeks

DRUG

Delamanid (DLM)

Administer 100 mg orally, twice daily for 24 weeks.

DRUG

Linezolid (LZD)

Administer 600 mg orally, once daily for 24 weeks.

DRUG

Levofloxacin

test group:Administer 800 mg orally, once daily for 24 weeks;control group:Administer 800 mg orally, once daily for 72 weeks

DRUG

Cycloserine

Administer 250mg orally, twice daily for 72 weeks.

DRUG

Clofazimine

Administer 100 mg orally, once daily for 72 weeks

All Listed Sponsors
lead

Wuhan Pulmonary Hospital

OTHER

NCT07198685 - 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province | Biotech Hunter | Biotech Hunter